Celldex Therapeutics, Inc.: Form 10-Q for the period ended Jun 30, 2018
Filed with the SEC on Aug 8, 2018 and accepted by EDGAR at Aug 8, 2018, 16:06 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2018-06-30. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 3 months2018-04-01 to 2018-06-30 | $2.8m | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Revenue | 6 months2018-01-01 to 2018-06-30 | $6.8m | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Research and development | 3 months2018-04-01 to 2018-06-30 | $21.4m | us-gaap:ResearchAndDevelopmentExpense |
| Research and development | 6 months2018-01-01 to 2018-06-30 | $43.3m | us-gaap:ResearchAndDevelopmentExpense |
| Operating income | 3 months2018-04-01 to 2018-06-30 | −$16.9m | us-gaap:OperatingIncomeLoss |
| Operating income | 6 months2018-01-01 to 2018-06-30 | −$136.5m | us-gaap:OperatingIncomeLoss |
| Income tax | 6 months2018-01-01 to 2018-06-30 | −$765.0k | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months2018-04-01 to 2018-06-30 | −$16.4m | us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic |
| Net income | 6 months2018-01-01 to 2018-06-30 | −$134.5m | us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic |
| Diluted EPS | 3 months2018-04-01 to 2018-06-30 | −$0.11 | us-gaap:EarningsPerShareBasicAndDiluted |
| Diluted EPS | 6 months2018-01-01 to 2018-06-30 | −$0.93 | us-gaap:EarningsPerShareBasicAndDiluted |
| Operating cash flow | 6 months2018-01-01 to 2018-06-30 | −$45.4m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 6 months2018-01-01 to 2018-06-30 | $591.0k | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Cash and equivalents | At period end2018-06-30 | $43.9m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2018-06-30 | $120.3m | us-gaap:AssetsCurrent |
| Total assets | At period end2018-06-30 | $178.4m | us-gaap:Assets |
| Current liabilities | At period end2018-06-30 | $20.0m | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2018-06-30 | $50.3m | us-gaap:Liabilities |
| Shareholders' equity | At period end2018-06-30 | $128.0m | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0001104659-18-050496. Last ingested by Listed: Nov 5, 2026, 19:04 ET. Listed shows no prices and gives no investment advice.